Publications by authors named "A R Patwardhan"
Molecular structure determination using electron cryomicroscopy (cryoEM) is poised in early 2025 to surpass X-ray crystallography as the most used method for experimentally determining new structures. But the technique has not reached the physical limits set by radiation damage and the signal-to-noise ratio in individual images of molecules. By examining these limits and comparing the number and resolution of structures determined versus molecular weight, we identify opportunities for extending the application of single-particle cryoEM.
View Article and Find Full Text PDFBackground: Treatment of diabetes and its complications is a primary health care expense. Up to 25% of people with diabetes will develop diabetic foot ulcers (DFUs). Removable cast walker (RCW) boots commonly prescribed for DFU treatment, promote healing, and provide offloading and wound protection.
View Article and Find Full Text PDFArticle Synopsis
- Chronotype influences pain sensitivity, as morning chronotype patients experience higher neuropathic pain intensity compared to those with intermediate chronotypes.
- The study utilized tools like the Morningness-Eveningness Questionnaire and various statistical analyses to assess the relationship between chronotype, pain intensity, and pain interference.
- Results indicate that factors such as depression, sleep quality, and BMI are significant predictors of pain scores, although the study's small and homogenous sample size limits generalizability.
Article Synopsis
- - Antagonists like Ziconotide and Gabapentin target CaV2.2 calcium channels to relieve chronic pain, but their clinical use is limited due to issues like narrow therapeutic windows and potential for misuse or side effects.
- - A new compound called C2230 has been identified as a blocker of CaV2.2 channels, showing multiple beneficial effects such as trapping the channel in an inactivated state and specifically targeting pain without affecting other ion channels or motor functions.
- - C2230 effectively reduced pain-like behaviors in various animal models and human neurons, suggesting it could be developed as a new analgesic with a unique binding mechanism that differentiates it from existing treatments.
Objectives: To assess the visual outcome of extension to 12-weekly intervals (Q12W) following 4 loading doses of intravitreal Faricimab injections as described in the TENAYA and LUCERENE trials for the management of treatment-naïve neovascular Age-related Macular Degeneration (nAMD).
Methods: A retrospective analysis was carried out on all treatment-naïve nAMD patients who started Faricimab intravitreal injections in the period between 1 September 2022 and 31 January 2023. The data collection included best corrected visual acuity (BCVA) at baseline, 12 weeks, 24 weeks and 52 weeks; Central Subfield Thickness (CST) at baseline, 24 weeks and 52 weeks; Number of injections at 52 weeks; treatment intervals at 52 weeks.